Characterizing metastatic tumors solely based on ER positivity or ESR1 status is insufficient, and there is a need for improved methodologies to select patients who remain endocrine sensitive after CDK4/6i treatment. This evidence concerns the gene CDK4 and metastatic neoplasm.